225 related articles for article (PubMed ID: 27755236)
1. Antiblastic drug-induced cardiotoxicity and cardioprotection: a compendium.
Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e1-e2. PubMed ID: 27755236
[No Abstract] [Full Text] [Related]
2. Antiblastic drug-induced cardiotoxicity and cardioprotection: a compendium.
Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S1-2. PubMed ID: 27183519
[No Abstract] [Full Text] [Related]
3. Cancer Therapy-Related Cardiac Dysfunction: Unresolved Issues.
Marwick TH
Can J Cardiol; 2016 Jul; 32(7):842-6. PubMed ID: 27343742
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity from anthracycline and cardioprotection in paediatric cancer patients.
Bassareo PP; Monte I; Romano C; Deidda M; Piras A; Cugusi L; Coppola C; Galletta F; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e55-e63. PubMed ID: 27755243
[TBL] [Abstract][Full Text] [Related]
5. A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
Maurea N; Spallarossa P; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e93-e104. PubMed ID: 27755247
[TBL] [Abstract][Full Text] [Related]
6. Routine Prophylactic Cardioprotective Therapy Should Not Be Given to All Recipients of Potentially Cardiotoxic Cancer Chemotherapy.
Davis MK; Virani SA
Can J Cardiol; 2016 Jul; 32(7):926-30. PubMed ID: 27245087
[TBL] [Abstract][Full Text] [Related]
7. Withdrawal of Heart Failure Medications in Cancer Survivors With Chemotherapy-Induced Left Ventricular Dysfunction: A Pilot Study.
Fadol AP; Banchs J; Hassan SA; Yeh ET; Fellman B
J Card Fail; 2016 Jun; 22(6):481-2. PubMed ID: 27036866
[No Abstract] [Full Text] [Related]
8. Left Ventricular Dysfunction and Chemotherapeutic Agents.
Clasen SC; Wald JW
Curr Cardiol Rep; 2018 Mar; 20(4):20. PubMed ID: 29520629
[TBL] [Abstract][Full Text] [Related]
9. Anthracycline-related cardiotoxicity in childhood cancer survivors.
Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
[TBL] [Abstract][Full Text] [Related]
10. Metabolomic Perspectives in Antiblastic Cardiotoxicity and Cardioprotection.
Deidda M; Mercurio V; Cuomo A; Noto A; Mercuro G; Cadeddu Dessalvi C
Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31590338
[TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity of cancer chemotherapy in clinical practice.
Jain D; Aronow W
Hosp Pract (1995); 2019 Feb; 47(1):6-15. PubMed ID: 30270693
[TBL] [Abstract][Full Text] [Related]
12. Myocardial Protection During Cardiotoxic Chemotherapy.
Witteles RM; Bosch X
Circulation; 2015 Nov; 132(19):1835-45. PubMed ID: 26553713
[No Abstract] [Full Text] [Related]
13. Cardiovascular imaging in the diagnosis and monitoring of cardiotoxicity: cardiovascular magnetic resonance and nuclear cardiology.
Pepe A; Pizzino F; Gargiulo P; Perrone-Filardi P; Cadeddu C; Mele D; Monte I; Novo G; Zito C; Di Bella G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e45-e54. PubMed ID: 27755242
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention.
Cadeddu Dessalvi C; Deidda M; Mele D; Bassareo PP; Esposito R; Santoro C; Lembo M; Galderisi M; Mercuro G
J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):315-323. PubMed ID: 29708912
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular imaging in the diagnosis and monitoring of cardiotoxicity: role of echocardiography.
Zito C; Longobardo L; Cadeddu C; Monte I; Novo G; Dell'Oglio S; Pepe A; Madonna R; Tocchetti CG; Mele D
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e35-e44. PubMed ID: 27755241
[TBL] [Abstract][Full Text] [Related]
16. Routine Prophylactic Cardioprotective Therapy Should Be Given to All Recipients at Risk of Cardiotoxicity From Cancer Chemotherapy.
Abdel-Qadir H; Nolan MT; Thavendiranathan P
Can J Cardiol; 2016 Jul; 32(7):921-5. PubMed ID: 27343746
[TBL] [Abstract][Full Text] [Related]
17. Cancer and the Broken Heart: Complications and Implications of Therapy-Related Cardiotoxicity.
Boyle DA
J Infus Nurs; 2018; 41(4):229-240. PubMed ID: 29958259
[TBL] [Abstract][Full Text] [Related]
18. [Heart failure].
Ozaki Y; Koganemaru S; Suyama K; Miura Y; Takano T
Nihon Rinsho; 2015 Feb; 73 Suppl 2():389-98. PubMed ID: 25831789
[No Abstract] [Full Text] [Related]
19. Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection.
Madonna R; Cadeddu C; Deidda M; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Spallarossa P; Tocchetti CG; Zito C; Mercuro G
Heart Fail Rev; 2015 Sep; 20(5):621-31. PubMed ID: 26168714
[TBL] [Abstract][Full Text] [Related]
20. Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity.
Wickramasinghe CD; Nguyen KL; Watson KE; Vorobiof G; Yang EH
Future Oncol; 2016 Mar; 12(6):855-70. PubMed ID: 26829050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
